B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

MAPK7

MOLECULAR TARGET

mitogen-activated protein kinase 7

UniProt: Q13164NCBI Gene: 559822 compounds

MAPK7 (mitogen-activated protein kinase 7) is targeted by 22 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MAPK7

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1alvocidib4.5291
2tozasertib4.3375
3ceritinib4.1965
4bosutinib4.0858
5bi 25364.0154
6nintedanib3.6136
7bms 3870323.4731
8tae 6843.4330
9fedratinib3.4029
10at 75193.3327
11jnj 77066213.0921
12lestaurtinib3.0420
13pf 037583093.0019
14danusertib2.9418
15pf 005622712.7715
16pha 6657522.7114
17bms 3455412.7114
18kw 24492.6413
19zotiraciclib2.5612
20rg 5472.087
21pf 038147351.795
22Crizotinib0.691

About MAPK7 as a Drug Target

MAPK7 (mitogen-activated protein kinase 7) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 22 compounds with documented MAPK7 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MAPK7 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.